ArticleHeliyon2025
Pan-cancer analysis of SOX2: Prognostic implications and potential as a therapeutic target in immune checkpoint modulation.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates SOX2 genetic, transcriptomic, and epigenetic alterations across over 30 cancer types. Significant downregulation of SOX2 expression was observed in colorectal adenocarcinoma, esophageal carcinoma, rectum adenocarcinoma, stomach adenocarcinoma, and testicular germ cell tumors, whereas its expression was upregulated in cervical squamous cell carcinoma, glioblastoma multiforme, lower grade glioma, lung adenocarcinoma, and lung squamous cell carcinoma. Survival analysis showed that low SOX2 expression correlated with better prognosis in bladder cancer, liver hepatocellular carcinoma, kidney renal clear cell carcinoma, and sarcoma, whereas high SOX2 expression was associated with poor prognosis in lung adenocarcinoma, and lung squamous cell carcinoma, glioblastoma multiforme, lower grade glioma. Although increased immune checkpoint expression is generally linked to poor prognosis, tumors with high SOX2 expression exhibited higher responsiveness to immune checkpoint inhibitors, suggesting that targeting SOX2 may improve immune checkpoint therapy efficacy. The study highlights SOX2 as a key factor in cancer prognosis and immune infiltration across multiple tumor types. Its expression is closely associated with immune-related genes and may serve as both a prognostic biomarker and a therapeutic target. These findings underscore SOX2's potential in regulating immune checkpoints and enhancing cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.